Skip to content

Behavioral Management of Phosphorus in Hemodialysis Patients

Behavioral Management of Phosphorus in Hemodialysis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02940743
Enrollment
40
Registered
2016-10-21
Start date
2018-04-23
Completion date
2018-05-01
Last updated
2018-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease (CKD), Hyperphosphatemia

Keywords

Hemodialysis

Brief summary

The purpose of this randomized clinical trial is to evaluate alternative technology-supported behavioral approaches to engaging 42 maintenance hemodialysis (HD) patients with persistent hyperphosphatemia in phosphorus binder adherence and dietary phosphorus restriction. Participants will be randomized to 1 of 3 intervention groups: (1) Education (Edu); (2) Edu + Self-Monitoring (SM); or (3) Edu + SM + Social Cognitive Theory (SCT)-based training program.

Detailed description

Investigators will evaluate the intervention in terms of feasibility and acceptability, behavior change at 12 and 24 weeks (reported phosphorus binder adherence, reported nutrient intakes, normalized protein catabolic rate), and clinical outcomes (serum phosphorus concentrations, symptoms). In addition, the impact of the different behavioral approaches on self-efficacy at 12 and 24 weeks, and the mediating effects of self-efficacy in facilitating behavioral changes and clinical outcomes will be examined.

Interventions

BEHAVIORALEducation (Edu)

This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.

BEHAVIORALSM intervention

During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).

BEHAVIORALSocial Cognitive Therapy (SCT)

This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Receiving thrice-weekly hemodialysis treatment for at least 3 months * 3-month average serum phosphorus concentration \>5.5 mg/dL

Exclusion criteria

* Unable to participate meaningfully in the combined Edu + SM + SCT intervention, including: * Unable to read and/or speak English * Self-monitoring application is currently available in English only (patients will not be excluded from participation on the basis of race/ethnicity) * Cognitively-impaired * Physically-impaired * Institutionalized or otherwise having limited control over diet * Life expectancy of \<1 year per dialysis center staff * Women who are pregnant or become pregnant during the study

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Hemodialysis (HD) patients that are eligible for the study24 WeeksMeasure of feasibility
Proportion of eligible patients who agree to participate24 WeeksMeasure of feasibility
Proportion of enrolled participants who complete the study24 WeeksMeasure of Acceptability

Secondary

MeasureTime frameDescription
Normalized protein catabolic rate (nPCR)24 WeeksThe nPCR is an objective measure of protein intake in HD patients based on the accumulation of urea nitrogen in blood between dialysis treatments
Frequency and severity of participant symptoms assessed via an investigator-developed questionnaire24 Weeks(itching, bone and joint pain, cramping) and phosphorus binders (difficulty defecating, loose or watery stools) will be self-reported via an investigator-developed questionnaire.
Balance Wise Self-Efficacy for Restricting Dietary Sodium in Hemodialysis Scale24 Weeksbe adapted to focus on adherence to phosphorus binders, dietary phosphorus restrictions and adequacy of protein intake. The self-efficacy questionnaire asks participants' to report their confidence in the next month that they will be able to complete various tasked related to the study intervention. An overall scale, and subscale scores for phosphorus binders, dietary phosphorus restriction and adequacy of protein intake will be computed by summing pertinent items for analyses.
Serum phosphorus.24 WeeksPre-dialysis serum phosphorus concentrations are a key secondary clinical endpoint for this intervention. Serum phosphorus is already being measured in participants as part of the routine monthly laboratory blood work, so this information will be obtained from the participant's medical charts.
8-item Morisky Medication Adherence Survey (MMAS-8)24 WeeksUsed to measure Binder Adherence, has been shown to be a valid and reliable measure of antihypertensive medication adherence
Reported dietary energy, protein and phosphorus intake2 Weeksparticipants will be directed to complete three, non-consecutive food records over the two-week period. Diet record days will include two weekdays (1 dialysis day and 1 non-dialysis day), and one non-dialysis weekend day.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026